News

Levodopa (L-DOPA) therapy is neuroprotective and prevents age-related iron accumulation in the substantia nigra, a brain region involved in Parkinson’s disease. The study with that finding, “L-DOPA modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson’s disease,” was published in…

A common depression treatment called agomelatine worsens Parkinson’s-related loss of dopamine-producing neurons, motor dysfunction, and protein oxidation, according to research in rats. The study with that finding, “Effects of Agomelatine in Rotenone-induced Parkinson’s Disease in Rats,” was published in the journal Neuroscience Letters. Neuroinflammation, oxidative…

Patients with hypertension may be at a higher risk for Parkinson’s disease, according to a review of population-based studies. The review, “Association between Hypertension and the Risk of Parkinson’s Disease: A Meta-Analysis of Analytical Studies,” appeared in the journal Neuroepidemiology. Hypertension may cause damage…

Invasive treatment approaches for advanced Parkinson’s disease have differential effects on disease-associated motor and non-motor symptoms, a real-life observational study shows. These findings suggest that selection of a treatment should be based on each patient’s particular clinical profile, researchers say. The study, “EuroInf 2: Subthalamic…

A new way of diagnosing Parkinson’s disease based on manifestations that appear decades before motor symptoms — the current hallmarks for diagnosis — might allow early diagnosis and even prevention. The study, “From Prodromal to Overt Parkinson’s Disease: Towards a New Definition in the Year 2040,” was published in…